Abstracts tagged "anti-TNF therapy"

Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Zuzana Tatar¹, Carole Migne², Mélanie Petera³, Estelle Pujos Guillot⁴, Philippe Gaudin^5,6, T Lequerré⁷, Hubert Marotte⁸, Jacques Tebib⁹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, ³Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, ⁴Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, ⁵Rheumatology, University Hospital, Grenoble, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, ⁸INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ⁹Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
Abstract Number: 2871 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Denis Choquette¹, Proton Rahman², Maqbool Sheriff³, Wojciech Olszynski⁴, Emmanouil Rampakakis⁵, Eliofotisti Psaradellis⁶, Francois Nantel⁷, Brendan Osborne⁸, Allen J Lehman⁹, Karina Maslova⁹ and Cathy Tkaczyk⁸, ¹Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada, ⁶JSS Medical Research, Montreal, QC, Canada, ⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ⁸Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Although the efficacy and tolerability of golimumab (GLM) in patients with ankylosing spondylitis (AS) has been demonstrated in several controlled clinical trials, it is…
Abstract Number: 89 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients with Rheumatoid Arthritis
Kyoko Honne¹, Ingileif Hallgrimsdottir², Chunsen Wu³, Ronnie Sebro⁴, Nicholas Jewell², Takeo Sakurai⁵, Masahiro Iwamoto⁶, Seiji Minota⁶ and Damini Jawaheer⁷, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²UC Berkeley, Berkeley, CA, ³University of Southern Denmark, Odense, Denmark, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Inoue Hospital, Takasaki, Japan, ⁶Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Studies of patients with rheumatoid arthritis (RA) to identify genetic biomarkers of anti-tumor necrosis factor (TNF) response have been conducted mostly in Caucasian populations.…
Abstract Number: 654 • 2015 ACR/ARHP Annual Meeting
Associations Between Skin Outcomes By Body Area Affected and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Alice B. Gottlieb¹, Bengt Hoepken², Luke Peterson³ and Peter C. Taylor⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²UCB Pharma, Monheim, Germany, ³UCB Pharma, Raleigh, NC, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) report poorer health-related quality of life (HRQoL) compared to the general population. As with psoriasis (PSO), it is…
Abstract Number: 1637 • 2015 ACR/ARHP Annual Meeting
TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Leslie Harrold^1,2, George W. Reed^1,2, Natalie Boytsov³, Carol L. Gaich³, Marc Mason⁴, Xiang Zhang³, Cynthia J. Larmore³, Sabrina Deveikis⁴ and Andre B. Araujo³, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: The purpose of this study was to describe the treatment patterns in biologic naïve initiators of TNF-inhibitors (TNFi) based on their disease activity over…
Abstract Number: 2734 • 2015 ACR/ARHP Annual Meeting
Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua¹, Nerea Torres¹, Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Begoña Ruiz-Argüello¹, Antonio Martínez¹, Rosaura Navarro⁶ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) inhibitors is constantly growing. As a consequence monitoring of drug levels (DL)…
Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 107 • 2015 ACR/ARHP Annual Meeting
FCGR3A-158V/F Polymorphism Is Associated with a Lower Response Rate to Tumor Necrosis FactorÂ Î± Blockers in Early Axial Spondyloarthritis: Data from the DESIR Cohort
Cécile LUXEMBOURGER¹, Anna Molto², Pascal Claudepierre³, Delphine Nigon¹, Alain G. Cantagrel¹, Maxime Dougados⁴, Arnaud CONSTANTIN¹ and Adeline Ruyssen Witrand⁵, ¹Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ²Hopital Cochin, Paris Descartes University, Paris, France, ³Hôpital Henri Mondor, Créteil, France, ⁴Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ⁵Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: The rs396991 polymorphism of FCGR3A alters the Fcγ Receptor Type IIIA function by enhancing or diminishing the affinity to the Fc of immunoglobulins (1)…
Abstract Number: 671 • 2015 ACR/ARHP Annual Meeting
Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Maxime Dougados¹, Owen Davies², Tommi Nurminen³, Geoffroy Coteur⁴ and Laure Gossec⁵, ¹Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ²UCB Pharma, Slough, United Kingdom, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Sorbonne Universités, UPMC Univ Paris 06 GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière Rheumatology Department, Paris, France
Background/Purpose: Discordance between patient (pt) and physician (phy) assessment of disease activity (DA) in spondyloarthritis (SpA) is recognized, with phys tending to score DA less…
Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…
Abstract Number: 2752 • 2015 ACR/ARHP Annual Meeting
Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in a Real-World Setting
Algis Jovaisas¹, Michael Starr², Denis Choquette³, Michel Zummer⁴, Regan Arendse⁵, Dalton Sholter⁶, Rafat Faraawi⁷, Jude Rodrigues⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, May Shawi¹⁰ and Karina Maslova¹⁰, ¹Capital North Therapeutics & Research, Ottawa, ON, Canada, ²Rheumatology, McGill University, Montreal, QC, Canada, ³Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Université de Montréal, Quebec, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Jude Rodrigues Medicine Professional Corporation, Windsor, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Unlike rheumatoid arthritis (RA), the pattern of joint involvement in psoriatic arthritis (PsA) is usually asymmetric. Furthermore, PsA may demonstrate oligoarthritis or polyarthritis,…
Abstract Number: 2877 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
John Kelsall¹, Denis Choquette², Proton Rahman³, Regan Arendse⁴, Michelle Teo⁵, Isabelle Fortin⁶, J Antonio Avina-Zubieta⁷, Emmanouil Rampakakis^8,9, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹, Francois Nantel¹² and Allen J Lehman¹⁰, ¹Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ²Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Medicine, Memorial University, St John's, NF, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁶Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁷Arthritis Research Canada, Richmond, BC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Enthesitis is characterized by inflammation at the insertion of ligaments, tendons, joint capsule, or fascia to bone, and represents a well-known characteristic feature of…
Abstract Number: 122 • 2015 ACR/ARHP Annual Meeting
General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study
Martin Soubrier¹, Sylvain Mathieu² and Elise Berthet³, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Remission of disease is the primary goal in chronic inflammatory arthritis, especially in rheumatoid arthritis. Traditional disease-modifying drugs like methotrexate and anti-tumor necrosis factor…
Abstract Number: 681 • 2015 ACR/ARHP Annual Meeting
Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from a Prospective, Observational Registry
Michael Starr¹, Michel Zummer², Denis Choquette³, Boulos Haraoui⁴, Dalton Sholter⁵, Regan Arendse⁶, Isabelle Fortin⁷, Louis Bessette⁸, Proton Rahman⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Allen J Lehman¹², Karina Maslova¹², Brendan Osborne¹³, Francois Nantel^14,15 and Cathy Tkaczyk¹³, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁹Medicine, Memorial University, St John's, NF, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that treatment outcomes are affected by disease-related aspects (e.g., disease severity and chronicity, treatment type and intensity) and patient-related factors…
Abstract Number: 1669 • 2015 ACR/ARHP Annual Meeting
Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis
Adrian Levitsky¹, Malin C. Erlandsson², Ronald F. van Vollenhoven¹ and Maria I. Bokarewa², ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Survivin is an oncological biomarker. In rheumatoid arthritis (RA), elevated serum survivin is common and has been used to predict disease onset and progressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].